Moleculin Biotech Inc

During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule10b5-1 trading arrangement or a non-Rule10b5-1 trading arrangement (each as defined in Item408 of Regulation S-K under the Securities Exchange Act of1934, as amended).

On* November 4, 2024,the Compensation Committee of the Board of Directors took the following actions in connection with the executive compensation for the2023/2024* compensation year (* June 1, 2023to May 31, 2024)with its named executive officers (Walter Klemp, President and Chief Executive Officer; Jonathan P. Foster, Executive Vice President and Chief Financial Officer; and Dr. Donald Picker, Chief Scientific Officer): (i) cash bonuses in the aggregate amount of$735,000* were granted based on the full achievement of the goals and objectives for the compensation year, however the payment of the bonuses was accrued and will be paid the earlier of a)364 days or b) approval by the CEO after consultation with the Board of Directors; and (ii) the Compensation Committee agreed that the accrued bonuses will earn interest at a rate of8% per annum.

On* November 4, 2024,the Compensation Committee and the Board of Directors agreed to issue each non-employee director a10*-year option to purchase10,000 shares of our common stock, under our shareholder approved stock plan, with vesting through the end of* April 2025*and an exercise price equal the closing price of our common stock on the date of the approval.

21